Xcout Intel
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Subscribe to see Tenax Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tenax Therapeutics, Inc. at a glance
Tenax Therapeutics, Inc. is a pharmaceuticals company headquartered in Chapel Hill, United States. It is publicly listed (TENX) with a market capitalisation of $276.8M. Xcout tracks 26 named people at Tenax Therapeutics, Inc., including Christopher T. Giordano (Chief Executive Officer, President & Director).
Tenax Therapeutics, Inc. leadership
- Christopher T. GiordanoChief Executive Officer, President & Director
- Chris GiordanoPresident and Chief Executive Officer
- Thomas R. StaabChief Financial Officer
- Tom StaabChief Financial Officer
- Stuart RichChief Medical Officer & Director
- Doug RandallChief Business Officer
20 more named people on record for Tenax Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Get Tenax Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Tenax Therapeutics, Inc. in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access